A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for ...

Golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as a monotherapy and ...

Incyte Biosciences Japan G.K. (INCY) on Monday reported the approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in ...

The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory follicular lymphoma, according to study results presented at ASH Annual Meeting and ...

BTK inhibitors work by blocking the BTK enzyme, which plays a role in B cell growth and proliferation. Pirtobrutinib is developed to overcome the tendency for cancer cells to become resistant to ...

Anti-CD20 B cell-depleting agents such as rituximab may offer a promising initial disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple ...

Rituximab offers an alternative to current immunosuppressive therapies for difficult-to-treat nephrotic syndrome. The best outcomes are seen in patients with steroid-dependent nephrotic syndrome who ...

Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis. HealthDay News — For patients with eosinophilic granulomatosis ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of rituximab, having considered evidence on the nature of anti-neutrophil cytoplasmic antibody ...